In addition, to assess tumour-antigen-stimulated T cells, we treated an additional cohort of mice bearing Nalm6 leukaemia with control and RASA2-KO CD19 TRAC CAR T cells to achieve tumour clearance and observed these mice to 116 days after CAR T cell injections. The gene discussed is CD19; the disease is neoplasm.